Trinity Biotech (TRIB) has made significant progress in its continuous glucose monitor (CGM) technology. The company recently received a European patent for a process that enhances the performance of its glucose biosensor, leading to faster and more accurate glucose readings. This development, coupled with the growing CGM market, positions Trinity Biotech for future success.
Abbott Laboratories is recalling certain FreeStyle Libre 3 sensors due to potential inaccurate high glucose readings. The faulty sensors could lead to serious health risks, including severe hypoglycemia. Abbott has also launched Lingo, a prescription-free continuous glucose monitoring system, for individuals seeking to improve their overall health.
A recent APK teardown suggests the upcoming Galaxy Watch 7 and Galaxy Watch Ultra could feature an AGEs index, continuous glucose monitoring, and family health tracking. These potential features offer insights into metabolic health, blood sugar levels, and family member well-being, but raise privacy concerns that Samsung is addressing with security measures.
A groundbreaking optical sensor has emerged as a promising candidate for continuous glucose monitoring, offering a non-invasive solution for diabetes management. This innovative device addresses the limitations of current invasive methods, such as finger pricks and microneedles, which can cause pain and discomfort. The sensor effectively differentiates between glucose and water in biological fluids, a crucial distinction that has hindered optical glucose sensing techniques in the past. With its miniaturization, Bluetooth connectivity, and wearable design, the sensor paves the way for convenient and continuous glucose monitoring, potentially transforming diabetes care.
